Design Synthesis and Evaluation of Hybrid Heterocyclic Derivatives against Mycobacterium Tuberculosis

Design Synthesis and Evaluation of Hybrid Heterocyclic Derivatives against Mycobacterium Tuberculosis

dc.contributor.guide	Kathiravan, M K
dc.coverage.spatial
dc.creator.researcher	Rahul Reddy, M B
dc.date.accessioned	2023-04-06T06:52:17Z
dc.date.available	2023-04-06T06:52:17Z
dc.date.awarded	2022
dc.date.completed	2022
dc.date.registered
dc.description.abstract	Mycobacterium tuberculosis (M.TB) bacillus causes tuberculosis (TB), is a chronic disease affecting lungs and other organs such as brain, intestines, kidneys and spine. TB is the most common infectious agent other than HIV/AIDS and is one of the top ten causes of death. Resistance to medicines develops in TB bacteria due to genetic alterations and recent molecular insights suggest that accumulation of mutation in the individual drug target genes is the primary mechanism of MDR-TB. The long treatment time, severe adverse effects and resistance problem prompts researchers in search of new anti-TBtargets and drugs newline
dc.description.note
dc.format.accompanyingmaterial	DVD
dc.format.dimensions
dc.format.extent
dc.identifier.uri	http://hdl.handle.net/10603/474947
dc.language	English
dc.publisher.institution	Department of Pharmacy
dc.publisher.place	Kattankulathur
dc.publisher.university	SRM Institute of Science and Technology
dc.relation
dc.rights	university
dc.source.university	University
dc.subject.keyword	Clinical Medicine
dc.subject.keyword	Clinical Pre Clinical and Health
dc.subject.keyword	Critical Care Medicine
dc.title	Design Synthesis and Evaluation of Hybrid Heterocyclic Derivatives against Mycobacterium Tuberculosis
dc.title.alternative
dc.type.degree	Ph.D.